Company Analysis Gilead Sciences
1. Summary
Advantages
- Dividends (3.64%) are higher than the sector average (0.5431%).
- The stock's return over the last year (58.71%) is higher than the sector average (-5.51%).
- Current debt level 5.27% is below 100% and has decreased over 5 years from 39.9%.
Disadvantages
- Price (106.5 $) is higher than fair price (6.19 $)
- The company's current efficiency (ROE=2.28%) is lower than the sector average (ROE=6.54%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
18 november 17:19 COVID-19 vaccine start-up files for IPO
2.3. Market efficiency
| Gilead Sciences | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0.7% | 0% | 3.8% |
| 90 days | 14.4% | -9.8% | -16.5% |
| 1 year | 58.7% | -5.5% | 7.9% |
GILD vs Sector: Gilead Sciences has outperformed the "Healthcare" sector by 64.21% over the past year.
GILD vs Market: Gilead Sciences has outperformed the market by 50.8% over the past year.
Stable price: GILD is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GILD with weekly volatility of 1.13% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (106.5 $) is higher than the fair price (6.19 $).
Price is higher than fair: The current price (106.5 $) is 94.2% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (240.57) is higher than that of the sector as a whole (64.63).
P/E vs Market: The company's P/E (240.57) is higher than that of the market as a whole (93.32).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (6) is higher than that of the sector as a whole (4.52).
P/BV vs Market: The company's P/BV (6) is higher than that of the market as a whole (5.61).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (4.02) is lower than that of the sector as a whole (33.51).
P/S vs Market: The company's P/S indicator (4.02) is lower than that of the market as a whole (10.28).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (65.34) is higher than that of the sector as a whole (-19.11).
EV/Ebitda vs Market: The company's EV/Ebitda (65.34) is higher than that of the market as a whole (19.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 87.87% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (87.87%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-26.26%).
5.4. ROE
ROE vs Sector: The company's ROE (2.28%) is lower than that of the sector as a whole (6.54%).
ROE vs Market: The company's ROE (2.28%) is lower than that of the market as a whole (5.31%).
5.5. ROA
ROA vs Sector: The company's ROA (0.7926%) is higher than that of the sector as a whole (-0.7601%).
ROA vs Market: The company's ROA (0.7926%) is lower than that of the market as a whole (6.12%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (11.06%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (11.06%) is higher than that of the market as a whole (10.94%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 3.64% is higher than the average for the sector '0.5431%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 3.64% has been steadily paid over the past 7 years, DSI=0.93.
Weak dividend growth: The company's dividend yield 3.64% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (816.25%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 75.65% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 15.04.2025 | Dickinson Andrew D Chief Financial Officer |
Sale | 106.4 | 266 000 | 2 500 |
| 15.04.2025 | ANDREW DICKINSON Officer |
Purchase | 106.4 | 266 000 | 2 500 |
| 12.02.2025 | Dickinson Andrew D Chief Financial Officer |
Sale | 102.22 | 14 073 200 | 137 676 |
| 12.02.2025 | Dickinson Andrew D Chief Financial Officer |
Purchase | 67.27 | 9 261 460 | 137 676 |
| 31.01.2025 | Dickinson Andrew D Chief Financial Officer |
Sale | 97.22 | 13 822 700 | 142 180 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
